elotuzumab

01/01/2018 - "We demonstrate significant antitumor efficacy of single-agent elotuzumab in immunocompromised xenograft models of multiple myeloma, which is in part mediated by Fc-FcγR interaction of elotuzumab with macrophages. "
10/01/2016 - "This review discusses the use of elotuzumab as an antimultiple myeloma agent and provides an update on the results of recent clinical trials evaluating the safety and efficacy of elotuzumab for the treatment of multiple myeloma."
01/01/2023 - "Efficacy of elotuzumab for multiple myeloma in reference to lymphocyte counts and kappa/lambda ratio or B2 microglobulin."
01/01/2021 - "In the first randomised study of high-risk multiple myeloma reported to date, the addition of elotuzumab to RVd induction and maintenance did not improve patient outcomes. "
01/01/2018 - "Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study."

08/15/2008 - "Administration of HuLuc63 significantly induces tumor regression in multiple xenograft models of human MM. These results thus define the functional significance of CS1 in MM and provide the preclinical rationale for testing HuLuc63 in clinical trials, either alone or in combination."
01/01/2018 - "Herein, we studied the NK cell independent effect of elotuzumab on tumor-associated macrophages using a xenograft tumor model deficient in NK and adaptive immune cells. "
05/09/2017 - "PD-1 blockade enhances elotuzumab efficacy in mouse tumor models."
10/01/2016 - "Upon binding to myeloma cells, elotuzumab exerts its cytotoxic effects through antibody-dependent cellular cytotoxicity, the antibody-induced selective lysis of tumor cells by activated natural killer (NK) cells. "
11/15/2017 - "The FDA approved elotuzumab with the following warnings and precautions: infusion reactions, infections, second primary malignancies, hepatotoxicity, and interference with the determination of complete response. "

01/01/2016 - "Clearance of elotuzumab increased with increasing body weight and weight-based dosing generated uniform exposures across a range of body weights. "

01/01/2020 - "We believe that the clinical course of this patient provides useful insights about the antimyeloma mechanism of elotuzumab."
11/08/2018 - "The hazard ratio for disease progression or death in the elotuzumab group as compared with the control group was 0.54 (95% confidence interval [CI], 0.34 to 0.86; P=0.008). "
10/01/2016 - "In these patients, the risk of disease progression or death was significantly reduced by 30% on elotuzumab. "
11/02/2022 - "Immunological changes and prevention of disease progression through elotuzumab therapy in refractory IgG4-related sclerosing mesenteritis."
05/01/2018 - "Based on the chest CT and lung pathology findings, the exclusion of infection and pulmonary edema, and according to the clinical course, we established a diagnosis of drug-induced ILD due to elotuzumab. "

12/01/2016 - "Patients with high-risk smoldering multiple myeloma who had been treated with elotuzumab monotherapy (10 or 20 mg/kg) in Study CA204011 (NCT01441973) underwent electrocardiogram (ECG) examination over 8-10 weeks (treatment cycles 1-3). "
12/01/2013 - "Elotuzumab represents an exciting future potential treatment option for patients with multiple myeloma, including those with relapsed and refractory disease, as well as in the induction and post-transplant maintenance settings, and possibly even for early therapy in patients with high-risk smoldering myeloma."
11/14/2022 - "report clinical and correlative results of a single-arm phase II trial of elotuzumab, lenalidomide, and dexamethasone in patients with high-risk smoldering myeloma. "